A repeat biopsy was obtained which confirmed poorly differentiated, ER–/ PR–/ HER2 negative carcinoma, TP53 mutations, as well as evidence of pharmacodynamic effect with tamoxifen. This evidence concerns the gene ESR1 and carcinoma.